Based on information surveyed from the Pharmaceutical Pricing and Reimbursement Information (PPRI) network, an overview on policies to enhance the uptake of biosimilar medicines in European countries was provided in an article written by the experts of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies and the Technical University Berlin. This country survey is supplemented by cost-saving estimates for German public payers if some of these policies had been implemented in Germany.
See article